text:
I've seen the videos of the songs children in Sderot sing as the Tzeva Adom (Red Alert) siren goes off. "My heart is beating boom boom boom boom boom… but I am overcoming because I am a little different… falling down – boom – but now we may stand up…" the song goes. I've been to Sderot before and seen the shelters and heard the residents' stories. But I've never talked to the children.
We walked into a kindergarten classroom and sat cross legged on the floor waiting for the students to come join us. One little boy immediately reminded me of myself – a little shorter than some of his classmates, a little bit klutzy, but undeniably happy to be in school. I motioned for him to come join me and asked him his name and age.
Mai was four-years-old and very excited to open the toy car I had in my hands. I spent the morning watching him roll that toy car back and forth in their play area outside, discover the joys of the Play-Doh ice cream set and run around with the mini wheelbarrow gathering sand.
He was no different than any four-year-old I have been a counselor for or ever babysat. Except when I looked around his classroom and school and asked him if he knew where to go during a Tzeva Adom siren he nodded his head and pointed where he would run. And then he put his head down and went back to games.
It occurred to me that in the summer of Operation Protective Edge, just a few years ago, he was barely a toddler. I remember being totally taken aback during that summer hearing of hospitals delivering children in bomb shelters and the first sounds those newborns heard was the sound of the Tzeva Adom. But to be an infant/toddler is even harder for me to imagine.
How were Mai's parents supposed to explain to him what that sound means? How were they supposed to make sure he was always able to make it to a shelter in time? How is it okay for this to be the norm for any child?
As I return to school this semester I am taking a class in child psychology. The syllabus says we will talk about normal child development from infancy through adolescence. Topics covered will include infant perception, early physical and psychological reasoning and conceptual development. Every word I read on the syllabus made me think of Mai and his friends and the town of Sderot.
I would love if there was some quick-fix to the reality of life in towns like Sderot, and yet unfortunately that is not the case. But I do know, that everything I learn this semester in this course, and even every time I am around a young child, I will think of Mai and the children in that kindergarten.


text:
Hello, Satsriakaal, Namashkaar, Vanakkam, Kem Cho, Baagunnara, Assalaam Valekhumm! Yeh hai Mayanagari!!! High time I spoke about myself and my interests!!! The world can take a backseat.
Sunday, June 12, 2011
House plants - Ghar Ki Shaan
3 comments:
Hi Maya,ReplyDelete
here are some suggestions - make sure you put the water you use for washing rice, dhal etc on the kadi-patta (not the mogra) - also the water from washing out the yoghurt container - there would help the kadi-patta grow.
The mogra, don't add miracle grow if you want flowers - that just gives more leaves! Use a potash fertiliser, or starve it a bit, that should work.
Happy growing
Great tip Asha. I will try it.
- AnonymousFebruary 20, 2013 at 6:21 PM
Wow! At last I got a web site from where I knowReplyDelete
how to actually get useful facts concerning my study and knowledge.
Stop by my web page: check this out

subset: commoncrawl


text:
Implications for obtaining consent for research on stored biological samples.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Wendler D, Emanuel E. The Debate Over Research on Stored Biological SamplesWhat Do Sources Think?. Arch Intern Med. 2002;162(13):1457–1462. doi:10.1001/archinte.162.13.1457
© 2018
Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002
The debate over informed consent for research on stored biological samples has enormous scientific implications. Unfortunately, there are no data on individuals' attitudes regarding when their consent should be obtained for such research.
Data were gathered using a telephone survey of 504 individuals living in the United States. Two cohorts were studied: (1) individuals who had participated in clinical research and contributed biological samples and (2) randomly selected Medicare recipients.
Of the respondents, 65.8% would require their consent for research on clinically derived, personally identified samples; 27.3% would require it for research on clinically derived samples that are "anonymized." For research-derived samples, 29.0% of the respondents would require their consent if the samples retain personal identifiers; 12.1% would require it if the samples are anonymized before the research is conducted. Also, 88.8% would want to be informed of results of uncertain clinical significance, and 91.9% would not impose greater safeguards on future research on a different disease.
Current practice and policy recommendations regarding research using stored biological samples may be inconsistent with sources' preferences in several respects. In particular, it appears that most sources want to control whether their samples are used for research purposes, are not concerned with the particular disease that will be studied, and want to receive results of uncertain clinical significance. Follow-up research will be needed to assess the generalizability of the current data.
RECENT ADVANCES in genetic and biomedical technologies have dramatically increased the scientific value of the hundreds of millions of human tissue and blood samples stored in laboratories across the country and around the world.1,2 This increased value has engendered a continuing debate over whether investigators should be required to obtain individuals' informed consent before conducting research on stored biological samples.3-9
Most stored biological samples were obtained during clinical care, for instance, following clinically indicated surgery. Other samples were obtained as part of individuals' previous research participation. Stored biological samples may be identified (linked to personal identifiers) or anonymous (not linked to any personal identifiers).
The principal risks of research on stored biological samples involve unwanted information flow. Such research may reveal facts about sources and their futures that they did not know and would not want others—employers, insurers, or family members—to know. Assessment of research on stored biological samples is difficult because there are no data on the magnitude of these risks. Moreover, most guidelines focus on clinical research that involves direct interaction with people. For instance, the Declaration of Helsinki refers to research "on" humans and research "involving" human subjects.10 It is often unclear to what extent these guidelines apply to research on stored biological samples.
In contrast, the US federal regulations ("Common Rule") explicitly exempt research on stored biological samples from review by institutional review boards and other regulatory safeguards, provided the sources cannot be "identified directly or through identifiers linked to the samples" (CFR §46.101). On this basis, some commentators argue that investigators need not obtain consent for research on stored biological samples that will be stripped of personal identifiers, or "anonymized." According to the American Society of Human Genetics (ASHG), anonymizing samples protects sources from risks and thus "eliminates the need for recontact to obtain informed consent."7
Critics respond that this view misunderstands the reason for obtaining informed consent. Informed consent is important because it allows sources to control whether their samples are used for research purposes. In the words of a US National Institutes of Health–Department of Energy Working Group on Ethical, Legal and Social Implications of the Human Genome Project, "If research is done on a sample for which the source can be identified, that source should be asked for his or her consent."8
Research on stored samples also raises a question of whether "sources" should be informed of results of uncertain significance.11,12 Researchers often do not have a clinical relationship with sources, and sources may misinterpret research results of uncertain clinical significance. For these reasons, the US National Bioethics Advisory Commission (NBAC) argues that the need to inform sources usually "does not apply to research using human biological materials."1 Others argue that investigators should provide sources with information gained about them.
These recommendations all depend on claims concerning what appropriate respect for sources requires. Unfortunately, there are no data on individuals' preferences; hence, commentators on both sides of the debate have been forced to base their recommendations on their own assumptions about individuals' preferences. To assess the accuracy of these assumptions, and provide data for the ongoing debates over research on stored samples, we surveyed 504 individuals with respect to the following questions: Do individuals from whom stored biological samples were obtained think their consent should be required for future research? Are these individuals more likely to think that consent should be required when the research concerns diseases other than the disease for which samples were originally obtained? Do they want results of uncertain clinical significance?
To avoid the need to recontact sources, many investigators now obtain consent for future research at the time biological samples are obtained. As a result, the debate over whether sources' consent should be required for research on stored biological samples principally concerns individuals who contributed samples more than 10 years ago. To assess these sources' views, we targeted older individuals who, as part of a research study, had provided biological samples that were stored for future research.
The present data were obtained as part of a 30-minute phone survey regarding individuals' attitudes regarding clinical research. Two cohorts were surveyed. First, potential respondents were selected from ongoing clinical research studies of older individuals who have a first-degree relative with probable Alzheimer disease at 4 geographically dispersed US research centers: Stanford University (Stanford, Calif), Duke University (Durham, NC), University of California, Los Angeles (UCLA), and the National Institutes of Health (Bethesda, Md). To participate in these studies, individuals had to be free from Alzheimer disease as judged by the investigators. To assess the generalizability of these individuals' views, a second cohort was randomly selected from a list of 35 million Medicare beneficiaries. Eligibility criteria were (1) at least 50 years old, (2) able to speak and understand English, (3) ability to understand the survey questions, and (4) sufficient hearing to answer questions over the telephone.
Potential respondents were sent a letter explaining the study, along with a postage-paid, self-addressed "opt-out" card, which allowed them to refuse. Those who did not return the card within 2 weeks were contacted. Verbal informed consent was obtained over the telephone by specially trained interviewers from the Center for Survey Research, Boston, Mass. Interviewers used a functional assessment of respondents' cognitive abilities: those who were able to negotiate an interview time and remember the survey questions were deemed competent.
Overall, 504 individuals completed the survey. Of the 263 eligible respondents from the Alzheimer studies, 246 completed the survey (response rate, 93.5%). Of the 551 eligible respondents identified from Medicare lists, 258 completed the survey (response rate, 46.8%).
Survey development occurred in the 7 following steps:
Comprehensive literature review
Draft survey development
Review by experts in survey methodology and genetics research
Survey revision
Cognitive pretest using in-person interviews with 3 elderly individuals who were participating in clinical research in the Boston area
Behavioral pretest with 3 additional elderly individuals who were participating in clinical research in the Boston area
Final revision.
The questions devoted to research with stored biological samples investigated the following 5 domains: research experience, provision of biological samples, whether consent should be required for research on stored samples, desire for research results, and sociodemographics.
Respondents' views on whether their consent should be required were assessed in 3 scenarios. Scenario 1 involved clinically derived samples: "Suppose you had surgery two years ago and during the operation your doctor took a sample of your tissue. Now a researcher would like to use that tissue in a research study." Scenario 2 involved research-derived samples: "Imagine you gave permission for a blood or tissue sample to be taken while you were participating in an Alzheimer disease research study. Later, the researcher wants to use this blood or tissue to study a new aspect of Alzheimer disease."
Some have argued that it is more important to obtain consent for additional research on diseases other than the disease for which samples were obtained. To assess this view, respondents who stated that their consent should not be required for additional research on Alzheimer disease were asked in scenario 3 whether their consent should be required "to study a different disease, like diabetes." In each scenario, respondents were asked whether their consent should be required for research using personally identified samples ("with your name attached") and anonymized samples ("after your name and identifying information had been removed from the sample"). For instance, respondents were asked, "suppose the researcher wanted to use your blood to study a different disease, like diabetes, should the researcher have to get your permission to use the leftover blood for that research if your name is still attached to the sample?" Response categories were "yes," "no," "don't know," and "it depends." Finally, respondents were asked whether they would want to be informed and/or want their physicians informed if "the researcher learned something about you but wasn't sure if it might affect your health."
Associations of responses with demographic characteristics (age, sex, income, education, race, religion, and research or Medicare cohort) were tested using a multivariate logistic regression model and a Wald χ2 statistic. An overall test was first performed (α = .05) before individual factors were examined. The study was approved by the institutional review boards at UCLA, Stanford University, Duke University, the National Institute of Mental Health (Rockville, Md), and the University of Massachusetts, Boston.
Table 1 outlines respondents' sociodemographic characteristics. Mean age was 65.2 years. The Medicare cohort resembled the average elderly American; individuals from the research cohort had significantly higher incomes, more formal education, and more women and were less likely to be retired and more likely to be white.13 There were no statistically significant differences in the responses to any questions between the research cohort and the Medicare cohort. Hence, these groups were collapsed for purposes of analysis.
Table 2 provides respondents' views on whether consent should be required for research on clinically derived (scenario 1) and research-derived (scenario 2), stored biological samples. For both clinically derived and research-derived samples, respondents who stated their consent should not be required when the samples retain personal identifiers are reported as believing that their consent should also not be required when the samples will be anonymized. Table 3 provides respondents' views on whether consent should be required to use samples for additional research on a different disease. None of the sociodemographic factors considered reached statistical significance. Finally, 88.8% of all respondents want to be informed and 82.1% want their physicians informed of research results of uncertain clinical significance.
Multivariate analysis revealed that older individuals (odds ratio, 1.43; 95% confidence interval, 1.01-1.92) and nonwhites (odds ratio, 2.56; 95% confidence interval, 1.23-5.30) were significantly less likely to think that consent should be required for research using clinically derived samples that retain personal identifiers. Otherwise, there were no significant associations between individuals' responses based on their sex, income, education, or whether they had previously participated in clinical research.
Current debates over consent for research on stored biological samples have taken place in the absence of data on sources' own views. The lone exception is the NBAC sponsored "mini-hearings" held in 7 US cities to assess the public's attitudes toward research with stored biological samples.14 To our knowledge, the present study provides the first systematic assessment of individuals' perspectives on this issue. The results suggest that there may be conflicts between people's attitudes and current recommendations in several important respects.
First, many policy recommendations endorse the same approach regarding consent for research on stored biological samples: either the source's consent is unnecessary or the consent should be obtained whenever possible. The present data suggest that it may depend on the samples in question regarding whether sources think their consent should be required. Two thirds of the respondents believe their consent should be required for research using clinically derived samples that retain personal identifiers. In contrast, just 1 in 8 believes their consent should be required for additional research using research-derived samples that were anonymized.
Most writers assess whether sources' consent should be required based on the risks involved. On this basis, most recommendations endorse very different safeguards for research-derived, identified samples vs clinically derived, anonymized samples. In contrast, essentially the same number of respondents thought their consent should be required in these 2 cases (27.3% vs 29.0%). This result appears to trace to respondents' attention to an issue largely ignored by policy recommendations: did sources ever give consent for the samples to be used for research purposes? Once consent for research purposes has been given, most respondents viewed additional consent for each type of research as unnecessary. This view suggests that once sources give their consent for clinically derived samples to be used for research purposes, it may be possible to regard these samples as equivalent to research-derived samples for the purposes of deciding whether to obtain sources' consent for additional research.
These data also suggest that individuals may not think it is necessary to specify which kind of research will be performed when obtaining biological samples initially. For instance, the model consent form endorsed by the US National Action Plan on Breast Cancer solicits consent for research on cancer and then separately solicits consent for "research about other health problems."15 Respondents' views suggest that including this distinction on consent forms may complicate the consent process without offering options that subjects find ethically meaningful. It will be important to assess this possibility in future studies. In particular, it will be important to assess whether individuals have concerns about certain research, such as research on drug abuse or mental illness.
Obtaining sources' consent for future research on stored biological samples allows investigators to conduct research on these samples only as long as the risks to subjects do not increase. As a result, investigators and institutional review boards should regularly assess whether future advances in research technologies introduce new risks, thus implying that a new consent may be needed for the riskier, future research. It will also be important to assess the public's understanding of the risks of research on stored biological samples.
Taken together, these data suggest applying a tentative general framework for obtaining consent for research using stored biological samples (Figure 1). Consent should be required for research using clinically derived, identified samples, but waived for additional research using research-derived, anonymized samples. The present data suggest that research using clinically derived, anonymized samples and research-derived, identified samples should be treated similarly. However, these cases also seem the most contentious.
Most respondents stated that their consent is not necessary, whereas a sizable minority thought that consent should be required. Provided that the risks of the research are minimal, one possibility would be to use an opt-out approach. When contact is feasible, investigators could notify sources of the research plan and allow them to refuse, by returning an opt-out postcard, or declining by telephone or e-mail. On this approach, investigators would have to make a good faith effort to inform sources, thus providing the minority who think their consent should be required with the chance to decline. However, consistent with the preferences of the majority, this process would not require investigators to obtain affirmative consent for minimal risk research using clinically derived, anonymized and research-derived, identified samples. Future research will be needed to assess whether it is acceptable to conduct such research without even opt-out consent when contact is not feasible and the risks are minimal.
A number of proposals endorse stricter consent requirements for additional research on diseases other than the disease for which research derived samples were originally obtained. These recommendations appear to conflict with respondents' views that this distinction does not affect whether their consent should be required. However, it is important to note that these data were obtained in response to questions about research on a different disease that was specified as diabetes. Further research will be needed to determine whether sources think that consent requirements should be stricter for research on potentially stigmatizing diseases, such as acquired immunodeficiency syndrome or alcoholism.
Finally, our respondents want to be informed and want their physicians to be informed of research results of uncertain clinical significance. These views contradict much of current practice in genetics research in the United States, as well as NBAC's recommendation that the need to inform subjects does not apply to research on stored biological samples. Future research should assess whether respondents' desire for research results of uncertain clinical significance reflects a lack of appreciation for the difference between clinically validated tests and research assays with no proven reliability or validity. In the meantime, researchers should be aware that the common practice of not divulging results of uncertain significance may prove upsetting to many research participants. In the absence of data that show that providing such information has a negative impact on sources or their families, these results suggest that researchers should consider appropriate mechanisms to allow sources who want such information to obtain it.
In 2 ways, the current data are relevant in determining what policies and recommendations should be adopted. First, a number of recommendations are based on what is required to ensure that research is respectful of sources and their wishes. For instance, whether individuals should be given research results of uncertain clinical significance depends, in part, on whether they want such data. Of course, individuals' views are not the only relevant consideration. In particular, it is also important to assess the amount of effort required to provide this information and the impact that providing it has on sources.
Second, it is widely agreed that investigators should determine what information to provide potential research subjects based on what information a "reasonable" person would want to know, supplemented by any information that specific individuals want. This "combined" standard, for instance, suggests that informed consent documents should describe the kinds of future research that might be conducted on samples being obtained from subjects when a reasonable person would want to know such information and when there is any reason to think that the specific individuals in question would want this information, even though most people would not want it.
Of course, as with any initial data, further study will be required to assess whether the present results can be generalized to other groups. For instance, it will be important to determine whether the present results can be generalized beyond older Americans. Because there were very few minority respondents, the present results may not accurately reflect minority groups' views. Furthermore, older individuals and nonwhites were significantly less likely to think their consent should be required for research using personally identified samples obtained during clinical care. This result goes against the assumption that nonwhites are more reluctant to participate in clinical research. Given the small number of minorities that were surveyed, additional research will be needed to assess these results. In particular, it will be important to assess whether nonwhites do not view research on stored samples as potentially exploitative in the way they may view research that involves more personal interactions.
Several potential limitations of the present data should be noted. The low response rate for the Medicare cohort may limit generalizability. However, the consistency of responses between the Medicare cohort and the Alzheimer research cohort and the lack of any sociodemographic predictors for most responses suggest no systematic bias. The questions regarding identified samples referred to samples "with your name attached." Future research should consider whether respondents are less likely to require consent for research using samples that are coded so that their names remain connected to the samples, but are hidden from the investigators conducting the research. The family history of Alzheimer disease may raise concerns about the cognitive capacity of the Alzheimer research cohort. However, these individuals were judged free of the disease by Alzheimer disease experts at the time of their research enrollment and periodically during their longitudinal study. Moreover, they were assessed to be functionally competent at the time of the present survey. Finally, respondents may not fully understand the risks and potential benefits of research on stored samples. Thus, the extent to which respondents were willing to allow research on stored samples may be a result of this misunderstanding.
The present data regarding sources' preferences suggest 5 possible changes in practice and policy on research with stored biological samples:
For research using clinically derived, identified samples, consider requiring consent the first time the samples are used for research purposes.
For research using anonymized samples for which sources previously provided consent for research purposes, consider not requiring further consent.
For further research using identified samples for which consent for research purposes has previously been obtained and anonymized samples for which consent for research purposes has not been obtained, consider not requiring sources' positive consent provided risks are minimal. Instead, consider using presumed consent with opt-out.
When determining whether sources' consent should be required, it may not be necessary to consider whether the samples were obtained originally for the disease being studied.
Barring evidence of a significant adverse impact on sources or the ability to conduct important science, researchers should consider developing appropriate mechanisms that allow individuals to obtain research results of uncertain clinical significance.
It is important to note, however, that these recommendations are based on data from a limited sample. Hence, it will be important to conduct future research to assess the generalizability of the present data to other groups and the suitability of these 5 recommendations.
Accepted for publication November 15, 2001.
We owe a great deal to the support of our collaborators: Gary Small, MD, Andrea Kaplan, Karen Miller, Ranga Krishnan, MD, Murali Doraiswamy, MD, Jessica Sylvester, Jerome Yesavage, MD, Cathy Fenn, Trey Sundlerand, MD, Judy Friz, PhD, and Sue Bell, MSW. We also thank Kim Elmo and the Health Care Financing Administration for providing the Medicare cohort and to Mark Sobel, MD, Roger Aamodt, MD, Rick Martinez, MD, Carol Freund, PhD, Kate Berg, PhD, Ben Wilfond, MD, Sarah Hull, PhD, Kiran Prasad, Brian Clarridge, PhD, and Diane Fairclough, PhD.
The ideas and opinions expressed are the authors' own. They do not represent any position or policy of the National Institutes of Health, Public Health Service, or Department of Health and Human Services.


text:
post Monday blues.
see more Fail Blog
sigh. Its one of the days.
Its not even a Monday for it to blamed at.
neverending phone ringing the only staff here is still on leave today's dateline for arbi submissiom and its still sitting on the Boss' desk client neverending stops by the office while the Boss conveniently went out I can't seem to focus on working on anythingNaah. All in a day's work.
the Husband is not feeling well
Yah had left for tudung shopping in Jalan TAR
Keep on looking for the reason that ticks you off, when actually you know the answer at the back of your head.
And you know there's nothing you can do about it.
Just because you think you know how to go about it and that you're used to it, doesn't mean its a walk in the park.
Nothing works.
Not even comfort food.


text:
Sumitomo Mitsui Financial Group Inc - 12 Year Stock Price History | SMFG
Historical daily share prices for Sumitomo Mitsui Financial Group Inc since 2006 adjusted for splits and dividends. Open, high, low, close (OHLC) data as well as percentage changes for multiple date ranges. Display 20, 50 and 200 day moving averages and export charts as images to use in articles and blogs. The latest closing price for Sumitomo Mitsui Financial Group Inc as of August 14, 2018 is 7.73.
|Market Cap
|Banks - Foreign
|SUMITOMO MITSUI FINANCIAL GROUP, INC., is a financial holding company established through a share transfer from Sumitomo Mitsui Banking Corporation. As a holding company, SMFG has functions such as strategic planning, management, resource allocation, strategic planning of information systems, financial management, investor relations, risk management, human resource management for group executives, and business auditing of the group as a whole. Sumitomo Mitsui Card Company, Limited, SMBC Leasing Company, Limited, SMBC Friend Securities and The Japan Research Institute are wholly-owned subsidiaries of SMFG.


text:
Re: Pilot during WWII in Phillipines
In reply to:
Pilot during WWII in Phillipines
Try to get his separation papers from the service, which should show his service areas and missions. For WWII air pilots try the Army. Pilots were usually either Navy or Army Air Corps members at this time. Cargo pilots tended to be Army (except the women who were a separate service group altogether).
I checked for his name online at NARA in the AAD database at www.archives.gov/ but could only find a similar name from South Dakota, for Ironcloud, Samuel P.


text:
Alderman - Morris Wedding - 1931 - VA
Hi guys,
While doing some general research I came across a paper from the Grayson-Carroll Gazette that was printed on January 29, 1931.I thought it might have some interest to someone along these lines.
Miss Nettie Alderman, daughter of Mr. and Mrs. W.E. Alderman, of Galax, and Dixie Morris, of Hillsville, were quietly married on January 22nd at the home of Rev. J.W. Morris, and left for a short trip to North Carolina. They came back the night of the 25th and will make their home in Hillsville.
All their many friends wish them a happy and prosperous married life.
Good luck,
Charlie Weaver


text:
Sign In
Username or Email Address
Remember Me
Not a member? Learn more about our community.
Hey mama! We know how hard you work so we've carefully curated a list of exclusive perks from mama founders we love. To recieve all hookups or have your brand included on our list, apply to join our network of ladybosses. We got you girl.
Most Popular Perks
Get 25% Off AELLA
2 Classes For The Price Of 1 & More With AKT
25% Off Graphic Design Services with Anelise Salvo
Get 25% Off August
Get 30% Off Cabbages & Kings
Get 25% Off Christine Alcalay
15% off Nursery Essentials
10% off Wanderlust event tickets in the US/Canada
15% off Massage Service at Chillhouse
20% off Beyond Yoga Apparel
$150 Off a Handpicked Vacation Home
20% off any full priced item
Get 15% off your first organic meal delivery program!
20% off monthly membership to Citibabes + $25 savings on their first class purchase
25% off one order
20% Off Your First Purchase From HATCH
Organic Modernism at 15% off
White on White Modern Furniture at 15% off
Gorgeous Home Decor From Filling Spaces
Free Trial Class at The Floor Dance Academy
Desired & Inspired Wedding Planning
Get 20% Off Event Design & Planning Services
Get 40% Off Huckle & Goose Meal Plans
Get a FREE Consultation + $500 Off E-Commerce Services
Get 20% Off NONA Handbags
Get 20% Off Coveted Things
FREE Consultation + 30% Off PR Services
Get 15% Off The Wellness Mercantile
FREE Consultation + 20% Off Web Design Services
FREE First Session + 10% Off TroupeFit Training Packages
Get 50% Off Shameless Jewelry
25% Off Poncho + Parker
Get 25% Off a Photo Session with Belle Augusta
Get 20% Off PLATEFIT Classes & Memberships
Get 20% Off VARLEY Activewear
Get 25% Off Olivia + Ocean Swimwear
Get 20% Off Business Plan Tool with Above The Glass
Get 20% Off Ezra & Edie Newly Launched Line
Get 20% Off Your First Photoshoot with Stevi Sesin
Get 20% Off goldno.8 Customizable Handbags
Get 20% Off Esther Blum's Nutritional Coaching Packages
Enjoy 15% off spa therapies and fitness classes at exhale.
Get 20% Off Framing at Simply Framed
Free Item With First Purchase Rockets of Awesome
Get 25% Off Wax Club
1 Month Free Membership BodyLove Pilates
Exclusive Rates Jenelle Hamilton PR
Get 25% Off A 2-Hour Photo Session Emma Feil Photography
Get 50% Off First Time Orders Meisterdish
Get $15 Off First Order Minibar Delivery
Get 20% Off Mason Lane Art
Get 20% Off 12|12
Au Fudge, Exclusive Party Rental Rates
Get 20% Off Richer Poorer
LA Child Care Discounts at Plus One Agency
Get 20% Off Sweaty Betty
Get 20% Off Ramy Brook
Get 30% Off Mignonne Gavigan
Get $50 Off First Pair of M. Gemis
20% Off In-Store Purchase Rebecca Minkoff
Get 3 Free Smoothies & Soups With Daily Harvest
Get 30% Off Ariel Gordon Jewelry
Get 25% Off ASH + AMES
25% Off Luxury Baby Sleepwear At Louelle
Get 20% Off Middleberg Nutrition
25% Off Purchase at Rose & Rex
25% Off Accounting Services at Logistis
$50 Off Your First Shoot at Flytographer
25% Off all Online Orders at Juice Served Here
20% Off Sitewide at Foodstirs.com
Free Complimentary Class at INSCAPE
20% Off First Aid Beauty Products
Free Hydrating Treatment at Drybar
$75 off with a purchase of $150 at ShopBURU
20% Off Baby Jive Products
One Hour of Free Business Coaching with Ashley Gartland
$30 Gift Card to EBTH
15% Off Orders at Babesta
15% Off Booking at Thompson Hotels
50% Off Your First Rental at Armarium
25% Off Chantelle
20% Off Artifact Uprising
20% Off Services with Matte Black
25% Off AKID Shoes
One Complimentary Month at Sawyer
25% Off Services and Products with Anouk Colantoni
30% off all Design Packages at Laurel & Wolf
25% off Website Development with Codeless
30% Off ACAMA
15% Off Booking with Jam with Jamie
15% Off Your First Purchase at Anine Bing
20% off the First Subscription Box From Parasol
25% Off Marisa Vitale Photography
20% off makeup services at Blushington
30% off your first order at Carbon 38
Reduced Rate for A + A Digital
$25 Off Splendid Spoon's Program 2.0
25% off Design Services with Kati Forner
Four Tickets to Sesame Place
25% off the Baby Sleep Whisperer
10% off and more at Namaste New York
15% off Pink Chicken Online and In-Store
20% Off at OldNavy.com
11th Class Free at SoulCycle
4 Bottles of Wine for $30 at Winc
$200 off a booking with Kid & Coe


text:
You have no items in your shopping cart.
Welcome to officeflux
In stock
Email to a Friend
3M Scotch Magic Tape
Check items to add to the cart or select all
3M Scotch Transparent Tape 500 18mm x 66m
3M Scotch StilettoTape Dispenser Stiletto-C
UHU Glue Stick 40 g
Hispapel White Envelope 10"x7", 90gsm, 10pcs/pack
Address: Al Barsha 1, Dubai, UAE
Working Days/Hours:Sun - Thur / 8:00AM - 6:00PM
Get all the latest information on Events,Sales and Offers. Sign up for newsletter today.
Enter your e-mail Address


text:
-This story has been corrected; please see final paragraph
The Office of the Scottish Charity Regulator has told a charitable foundation in Shetland that it is not allowed to invest in a local project until its new board has had a chance to decide on whether to do so.
The Shetland Charitable Trust, which has assets of more than £200m, has a board made up almost entirely of Shetland Island councillors, appointed ex officio.
According to a report by the OSCR, the board met on 30 April and decided to invest £6.3m in the Viking Energy wind farm project, which is part-owned by the council and in which the OSCR says the trust has previously invested £3.42m.
The OSCR report says that the local elections that were held on 3 May could lead to the appointment of up to 22 new trustees, and that the board should not make a large-scale investment decision within days of such potentially big changes.
It says it is difficult to see how the trustees are "acting in the best interest of the charity and with appropriate care and diligence".
The OSCR is already monitoring governance at the trust because of "concerns regarding systemic conflicts of interest". A trust proposal earlier this year to replace the existing structure with a board of seven councillors and eight other members is being considered by the regulator.
- The report by the OSCR did not say that the board met on 30 April. It said the board was due to meet on that date to consider the investment in Viking Energy. The trust said today it was told by the OSCR it could not make a binding decision and so did not meet. Apologies for the mistake.


text:
Snerd, the young groundhog who predicts the end of Garner's winter, will again be center stage on Tuesday. If you have children, or if you're a big child yourself, this is a great opportunity to get outdoors, break up the hum drum routine of the work week and school week.
We wish we could tell you Snerd's prediction will be true and you'll have a great harbinger of weather to come, but Garner's Groundhog Day celebration is much more than that. It's a chance to learn about wildlife of all kinds and discover new things about the world around us.
In our daily rush of life, we rarely think about our place in the ecology of this world and, if we do, we almost certainly don't think about how other living things play just as critical a role as we do. You can learn those things in just a few hours at White Deer Park on Tuesday. And, it'll be fun. How often do you get to see a groundhog up close and personal?
Events like this one make our community unique. They give people a reason to explore Garner and its environs. When they do, they learn that events like Groundhog Day contribute to the quality of life in our town. They make it a great place for children and families. They manage to combine learning with fun and, let's face it, there aren't too many ways to do that.
It's no secret for those who live in Garner that the quality of life is high. Groundhog Day is our opportunity to share that fact with people from all over.
So be sure to take a little time on Tuesday to venture out to White Deer Park, hear from Snerd and learn something you didn't already know.


text:
I am actress, still trying to make my foothold strong in Bollywood. I had made a debut in Bollywood in 2004 but that went unnoticed and I moved on to south industry.
Play this game
No Members yet
Tron: Legacy (2010)Actor
Transmorphers: Fall of Man (2009)Actor
King of the Lost World (2005)Actor
Brilliant (2004)Actor
Snakehead Terror (2004)Actor
Contagion (2002)Actor
List of Bruce Boxleitner movies
Claudia Cardinale
James Coburn
Garrett Hedlund
Ashley Judd
Copyright 2010-2013: Gomolo. All Rights reserved. | Terms | Privacy


text:
About Us
Contact Us
SPM Info Blog
A Case in Point
Assigning Resources
Choosing an Organizational Form
Considering Dependencies
Creating the Work Breakdown Structure
Defining the Goal and Scope of the Software
Determining Project Risks
Developing the Software Requirements Specification
Eliciting Requirements
Estimating Duration and Cost
identifying the tasks and activities
Introduction to Software Engineering
Managing Domain Processes
Process Overview
Scheduling the Work
Selecting a Project Team
Selecting Software Development Life Cycles
Software Size and Reuse Estimating
Popular Posts:
The Rapid Application Development (RAD) Software Development Life Cycle Mod
The V-Shaped Software Development Life Cycle Model
Selecting an Appropriate Software Development Life Cycle Model
The Incremental Software Development Life Cycle Model
The Activity ID Process
Recent Posts:
Reliability Tools
Fault Tolerance
Fault Removal
Fault Prevention
Fault Forecasting
April 2013
May 2013
June 2013
July 2013
August 2013
September 2013
October 2013
November 2013
December 2013
January 2014
February 2014
March 2014
April 2014
May 2014
June 2014
August 2014
September 2014
October 2014
November 2014
December 2014
January 2015
February 2015
March 2015
April 2015
May 2015
June 2015
July 2015
August 2015
January 2016
February 2016
January 2017
May 2017
Popular Tags:
Life Cycle
Software Development
Software Project
Project Manager
Project Management
Software Engineering
Software Development Project
Software Product
Software Project Management
Gantt Chart
Configuration Management
Project Team
Product Development
Software Process
Tracking Process - Monitoring Compliance of the Project Team
Tracking Process - Monitoring Compliance of the Project Team
Views (
On April 16, 2013, In
by Admin
Project Competency 21:
Tracking Process - Monitoring Compliance of the Project Team
Part of the software quality assurance function, this skill includes tracking project execution against defined processes, recognizing deviations, and knowing what to do about them.
In "A Case in Point" little or no process tracking is performed, since there is little or no defined process, and the project spins out of control. "Managing Domain Processes" and "Software Metrics" talk about how to describe and manage project domain processes using metrics, while "Project Tracking and Control", "Software Quality Assurance" and "Continuous Process Improvements" show the skills required to monitor compliance of the project team to defined processes.
Project Competency 22:
Tracking Project Progress - Monitoring Progress Using Metrics
Many projects burn energy but don't get anywhere. A key project management skill is being able to track real progress, not just effort. This skill relates to metric selection and development monitoring, and contains earned value analysis and project buffer management.
The following figures show but two of the many software tracking tools that graph progress metrics. As shown in "What Is a Phase" figure, tracking progress is an essential task that spans the life cycle (note "Implement Problem Reporting Methods," under "Project Management and Control").
The sections on controlling a software project ("Project Tracking and Control" & "Continuous Process Improvement"), introduce methods and tools for tracking progress. "Project Tracking and Control" is all about project tracking and control, and shows how to use these tools to assess the real progress being made by the project team. The case study uses few progress tracking techniques so they think they are 90 percent complete all the time.
project management
life cycle
Fault Tolerance
Fault Removal
Fault Prevention
Fault Forecasting
SWEBOK and the SEI CMM
Introduction to Software Engineering
Steps in Developing a Risk Management Plan
Project Risk and the SEI
What Is Risk Management
Determining Project Risks
Evaluating the Project SRS
Benefits of an SRS | Building the SRS
Developing the Software Requirements Specification
Requirements and Quality Function Deployment
Requirements Management and the SEI CMM
Eliciting Requirements
Scheduling the Work
Brainstorming Dependencies and Activities
What Are Dependencies
What Is an Organization
Choosing an Organizational Form
Identifying and Documenting the Project Roles and Skills Needed
Assigning Resources
Estimating Duration and Cost - Summary
SLIM - A Mathematical Model
Detailed COCOMO
Basic COCOMO Phase Distribution of Effort and Schedule
The SEI CMM and Estimating
Estimating Duration and Cost
Getting Started with Software Sizing: Estimating Begins with Planning
Problems and Risks with Estimating Software Size
The SEI CMM and Estimating
Software Size and Reuse Estimating
The Activity ID Process
Characteristics of Tasks and Activities
Identifying the Tasks and Activities
Building a WBS for Software
Approaches to Building a WBS
What Is a Work Breakdown Structure
Creating the Work Breakdown Structure
The Software Project Management Plan
Project Planning
Defining the Goal and Scope of the Software
Providing the Total Solution
Working Together Requires a Framework
The Whole Is the Sum of the Parts
Where We Are in the Product Development Life Cycle
Selecting a Project Team
Project Selection Models
Defining the Process Domain
Managing Domain Processes
Customizing the Life Cycle Model
Selecting an Appropriate Software Development Life Cycle Model
The Spiral Software Development Life Cycle Model
The Incremental Software Development Life Cycle Model
The Rapid Application Development (RAD) Software Development Life Cycle Mod
The V-Shaped Software Development Life Cycle Model
International Organization for Standardization (ISO)/IEC 12207
The SEI CMM and the Life Cycle
Why Are Software Development Life Cycles Important
What Is a Software Development Life Cycle
Selecting Software Development Life Cycles Relation to the 34 Competencie
How to Use 1074
IEEE 1074 - Process Map for Software Life Cycle Process
SEI CMM Level 3 Is the Defined Level
Learning Objectives for Process Overview
Where We Are in the Product Development Life Cycle
Key Points of Process Overview
Process Overview
A Case in Point
Documenting Plans - Identifying Key Components
Project Management Skills
Understanding Development Activities - Learning the Software Development Cy
Tracking Product Quality - Monitoring the Quality of an Evolving Product
Tailoring Processes - Modifying Standard Processes to Suit a Project
Performing the Initial Assessment - Assessing Difficulty, Risks, Costs, and
Evaluating Alternative Processes - Evaluating Various Approaches
A Brief Description of Product Management Skills
Product Development Techniques
What Is a Phase
What Is Project Management
What Is a Project
What Is Software Project Management
Surveying the Foundations
Introduction to the 34 Competencies
Selecting Metrics - Choosing Appropriate Metrics
People Management Skills
The contents available on this website are copyrighted by TechPlus unless otherwise indicated. All rights are reserved by TechPlus, and content may not be reproduced, published, or transferred in any form or by any means, except with the prior written permission of TechPlus.
© Copyright 2018 SPMInfoBlog.
Designed by


text:
Alastair Hunter Gray
Alastair Hunter Gray received a first class degree in Art & Design from Leeds University, specialising in sculpture. His interest in the physical properties of materials is a central theme that binds together work encompassing college photography and installation.
His current work relies on the creative processes of others. He explores the possibilities in re-appropriating unwanted or discarded elements made in an art studio. Elements such as off-cuts from a guillotine, old screen-print material or masking tape found on the floor are given equal importance in forming new compositions. These materials are brought together in ways which imbue them with new purpose far removed from their makers' original intention.
The collages are arraigned on slabs of polished birch ply and finally trapped under a layer of resin. This resulting work becomes an object as well as a surface (staying true to his sculptural routes) and the resin unifies the composition in a way that brings a sense of democracy to the disparate elements which create it.


text:
A XAVIER University-Ateneo de Cagayan student placed sixth among the 2,472 who took the Electronics Engineer Licensure Examination given by the Board of Electronics Engineering last March 28-29, 2009.
Only 598 passed the exam.
Gian Carlo J. Estorba, 21, had long dreamed of topping the licensure exam but had abandoned the idea after he was thrust to work just two months after graduating cum laude at Xavier University-Ateneo de Cagayan in 2008.
Estorba works as an assistant aircraft technical specialist of Philippine Airlines.
The eldest child of five children of Virgilio L. Estorba, a harvester/surveyor at Del Monte Philippines Inc., and Josie L. Jamodiong, Gian Carlo had aspired to become an electronics engineer since he was in sixth grade.
The Estorbas are from the town of Libona in Bukidnon.
Teachers at XU described him as a "good student." He has been topping his classes from elementary to college.
Estorba has been consistently included in the Dean's List and studied as a scholar of the Department of Science and Technology and the university until his fifth year in college.
Giving more time to academics, he was only affiliated with Association of the College of Engineering Students (Aces) and Junior Institute of Electronics and Communications Engineering (IECEP) of the university.
However, he was involved in various academic competitions in the College of Engineering, both within the walls of the university and even in the national level.
His achievements include his being first runner-up during the 28th ECE National Interscholastic Quiz Show in Manila late last year. He was declared champion during the Mindanao Leg of the 4th Sweep Innovation and Excellence Awards Roadshow Online Quiz by Smart in Davao in 2007.
He had originally planned to take his review in Cebu for five months after graduation and take the board exam on October 2008. However, financial constraints made him decide to take the March 2009 exam instead.
He was able to take his review classes in Manila when he was given the opportunity to work with PAL. However, he largely missed his review sessions being a full-time worker at PAL.
Nevertheless, Estorba said he made it to top 10 by depending on these things: "mastery of the basics", a little help from the review center, the inspiration he got from his family and loved ones, and of course, prayers.
"If you have mastered the basics, you can always make an intelligent guess. Take out all the stored knowledge in your think tank and use them. And for questions where you really can't make intelligent guesses, this is where the role of prayer comes in," Estorba said.
Gian Carlo (left) in his friendster account


text:
2017 ASHP House of Delegates Candidates (Virginia)
This year, we have seven (7) nominees to the ASHP House of Delegates which will meet on two separate occasions at the 2017 ASHP Summer Meeting in Minneapolis, MN this June. Additionally, there will be two virtual House meetings in March and November
Below you will find the biographies of our candidates. An electronic ballot is being distributed to ASHP members living in Virginia.
Candidates are listed alphabetically by last name:
Below you will find the biographies of our candidates. An electronic ballot is being distributed to ASHP members living in Virginia.
Candidates are listed alphabetically by last name:
Scott Anderson, PharmD, MS: Scott is a Senior Pharmacy Application Analyst at the University of Virginia Health System in beautiful Charlottesville, Virginia. He provides analysis and support for multiple pharmacy information and automation systems, with a focus on developing clinical decision support and pharmacy revenue integrity solutions within the electronic health record. Scott earned his Bachelor of Arts in Journalism from the University of Minnesota Twin Cities, Doctor of Pharmacy from the University of Illinois at Chicago, and Master of Science in Health-System Pharmacy Administration from the University of Pittsburgh. After completing a PGY-1 pharmacy residency at the University of Pittsburgh Medical Center, he then helped to create and complete a PGY-2 Pharmacy Informatics residency at the University of Virginia Health System. He is a Clinical Assistant Professor with the VCU School of Pharmacy and is a preceptor for students and residents. He has served two terms as Region I President for the Virginia Society of Health-System Pharmacists as well as two terms as an Alternate Delegate representing Virginia, and was honored to receive the VSHP New Practitioner Award in 2015. Scott has also served on the Section of Pharmacy Informatics and Technology Education Steering Committee and as a student poster mentor and professional poster reviewer for ASHP.
Patrice Dupart, PharmD, BCPS, MSHCM: Patrice is a respected Pharmacy Leader with experience in pharmacy supply chain and 340B regulations, pharmacy automation, clinical pharmacy, and hospital pharmacy operations. Her career as a pharmacist in Louisiana, New Jersey, and Virginia spans more than 15 years. Dr. Dupart received her Doctor of Pharmacy degree from Xavier University of Louisiana and her Masters in Health Care Management from the University of New Orleans. She is a Board Certified Pharmacotherapy Specialist since 2008. She was selected to attend the ASHP Pharmacy Leadership Institute at Boston University Questrom School of Business in 2015. Dr. Dupart began her career as a pharmacy student intern and later completed her PGY-1 residency at Ochsner Foundation Hospital. Her first pharmacist role was as a Clinical Coordinator at Baptist Medical Center and she was later promoted to Pharmacy Operations Manager. In 2005 she assumed her first role as Director of Pharmacy at Hancock Medical Center. Over the next several years Dr. Dupart held several positions during her tenure at Ochsner Health System including Director of Pharmacy Services and System Director of Pharmacy Supply Chain. Since 2014, she has been in the role of Senior Director of Pharmacy for Inova Fairfax Medical Center overseeing both the inpatient and outpatient pharmacy areas. While at Inova, she has several accomplishments to her credit, including the expansion of the Pharmacy Clinical program to include Clinical Specialists in Infectious Diseases, Cardiology, and Pediatric Oncology; the creation of the PGY-2 Emergency Medicine residency program; the installation of two IV robots; and streamlining of the 340B drug program. At Inova she is constantly working to advance the role of pharmacy by employing the Pharmacy Practice Model Initiatives to guide areas of focus. She has worked to incorporate Inova's pharmacists and technicians into new decentralized activities like medication reconciliation in the emergency department and discharge counseling for select high acuity patients. Dr. Dupart currently chairs or co-chairs several medical staff and/or quality improvement committees advancing medication safety, clinical research, and pharmacy clinical services. She also serves as the Administration Preceptor for Pharmacy students and residents. She is an active member of organizations such as the American Society of Health-System Pharmacists (ASHP) and the President –Elect for the Virginia Society of Health-System Pharmacists (VSHP). She has served on several state wide committees and has presented at the state affiliate annual meeting.
Lisa Hammond, PharmD, BCPS: Lisa is the Manager of Clinical Pharmacy Services at Winchester Medical Center in Virginia. Her responsibilities include: coordinating patient care clinical services, formulary management, patient safety, and drug shortage management. She is also Adjunct Assistant Professor of Pharmacy Practice at Bernard J. Dunn School of Pharmacy, Shenandoah University. She also serves as a preceptor for the PGY1 residency program, fourth year student pharmacists and Pharm.D./MBA students. Lisa earned her B.S. in Pharmacy from Massachusetts College of Pharmacy and her Doctorate of Pharmacy from the University of North Carolina at Chapel Hill. She earned Board Certification in Pharmacotherapy in 2006. Lisa has served the pharmacy profession in State and National leadership roles. She represented VSHP in the ASHP House of Delegates for 2 years. Lisa has been VSHP regional president elect as well as president of Region 7. She served as Chair of the Organizational Affairs Committee for 5 years, and served 6 years as Political Action Committee Chair. Lisa was honored with the VSHP Clinical Pharmacy Practice Achievement Award, and as Preceptor of the Year at Bernard J. Dunn School of Pharmacy, Shenandoah University. Most recently honored with the 2015 National Master Preceptor Recognition Award from AACP.
Katelyn M. (Pontore) Hipwell, PharmD, MPH: Katelyn is from Cranesville, Pennsylvania. Currently, Dr. Hipwell is the manager of pharmacy clinical operations at the University of Virginia Health System. She completed her two year Health-System Pharmacy Administration Residency at Allegheny Health Network in Pittsburgh, Pennsylvania, which included the completion of a Master of Public Health degree from the University of Pittsburgh. She received her Doctor of Pharmacy degree from West Virginia University. Dr. Hipwell is eager to become involved with the opportunities VSHP has to offer and explore Virginia.
Julie K. Kidd, PharmD, BCPS, MPH: Julie completed her pre-pharmacy curriculum at Samford University in Birmingham, AL and then attended McWhorter School of Pharmacy at Samford University where she received her Doctorate of Pharmacy degree. After graduation, she completed a pharmacy practice residency at the University of Virginia (UVa) Health Systems. She has practiced as a clinical pharmacist at UVa Health Systems as well as Oregon Health and Sciences University (OHSU) in Portland, Oregon in the areas of surgery, internal medicine, and neurology. While in Portland, she received her Master's in Public Health (MPH) from OHSU. She now is a professor of Pharmacology and Epidemiology at Edward Via College of Osteopathic Medicine (VCOM) and spends time at Academic Primary Care Associates (APCA) as a clinical pharmacist. At APCA, she provides medication therapy management services as well as precepts 3rd year medical students during the Early Clinical Experiences (ECE). While not at work, she loves spending time with her husband and two sons as well as yoga, running, and gardening.
Craig Kirkwood, PharmD: Craig is the Assistant Director for Pharmacotherapy Services at VCU Health. He came to Richmond after completing his PGY2 Drug Information Residency in Chapel Hill. Craig has been actively involved in professional organizations at the state and national level over the past 30 years. He has been active at different stages of VSHP over the years. Initially he was an engaged member of the Professional Practice Committee; moderator and/or presenter for New Drugs updates, Spring and Fall Seminars; representative for VSHP at Southeast States Conference; and the co-sysop of the VSHP bulletin board (before the web site). During that period he was also the Vice President Elect and Vice President representing Region IV, and a Curbside Consultant at Fall and Spring seminars. Craig is currently serving in the first year of his second term as the VSHP Secretary. He served as a VSHP delegate at the House of Delegates during the Denver Annual Meeting four years ago, and last year at 2016 House of Delegates in Baltimore. At the national level, initially Craig was involved with ASHP (SIG on Drug and Poison Information Practice; chair and member of multiple advisory groups; preceptor of and selections committee member for Research and Education Foundation, Drug Information Fellowship; and more). Most recently he been very active with the University Health-System Consortium as a Pharmacy Council committee member (multiple committees), vice-chair and chair (Performance Improvement & Compliance Committee), as well as an Executive Committee member, national speaker and webinar participant.
Kelly Martin, PharmD, MS, BCPS: Kelly is a Pharmacy Manager at Virginia Commonwealth University Health System (VCUHS) in Richmond, Virginia. In her current role, Kelly is leading the development and expansion of Specialty Pharmacy services for VCU Health. This growth is currently focused on building relationships with the hepatology clinical team and patients, coordinating and overseeing prior authorization and reimbursement services, and standardizing daily processes for specialty medication distribution. Kelly transitioned into this role after serving as an Inpatient Pharmacy Manager for 3 years at VCUHS. Kelly completed a combined two-year administrative residency program at the University of Wisconsin Hospital and Clinics in Madison, Wisconsin, also earning her Masters of Science in Health System Pharmacy Administration. Kelly received her Doctorate of Pharmacy from the University of North Carolina - Chapel Hill and a Bachelor of Science degree in Microbiology from the University of Florida in Gainesville, Florida. Kelly is an active member of the Virginia Society of Health System Pharmacists (VSHP) and is currently serving as President-Elect of Region 4. Kelly also serves on the Vizient Specialty Pharmacy Committee and is an active member of ASHP, serving as Vice-Chair of the ASHP Section Advisory Group on Leadership Development. Kelly is passionate about developing leaders in all aspects of the profession of pharmacy, with an emphasis on guiding and motivating student and resident leaders. Kelly is interested in serving as a Virginia Delegate to the ASHP House of Delegates to represent the voice of all pharmacists and other pharmacy personnel from the Commonwealth of Virginia. Kelly had the opportunity to participate in the 2015 House of Delegates in at the ASHP Summer Meeting in Denver, Colorado, serving as an Alternate Delegate. Through this experience, Kelly discovered a great interest in and passion for the pharmacy practice policy development and approval process. Kelly would be honored to represent practitioners from throughout the Commonwealth of Virginia to ensure that new and existing policies continue to provide framework that allows pharmacists to practice to the top of their license and creatively serve patients throughout Virginia.


text: CHICAGO --Officials say they've beaten the bug, declaring victory over the infestation of Asian long horned beetles."The Asian long-horned beetle has been officially eradicated in the entire state of Illinois," said Bruce Knight, US Dept. of Agriculture. To commemorate the declaration, officials threw symbolic shovels of dirt on a newly planted tree that once might have been destroyed by the beetles. The event was held in Ravenswood, where the bugs were first found nearly 10 years ago. The one-and-a-half inch long insects are believed to have arrived here in packing material from China. Their larvae burrow into trees, killing them. More than 1,700 trees were removed in the battle against the bug. The last sighting was in Chicago's Oz Park in 2003. To prevent re-infestation, all wooden packing materials from overseas have to be specially treated.


text:
Please raise your hand if you've ever felt the need to understand what makes a good photo and how to take good photos?
As a beginner, when you look at your photos you're hit with the realisation that these photos don't feel good enough, killing any creative inkling you may have felt.
Well, there's good news…
…taking a good photo with your DSLR doesn't have to be that daunting.
With the right understanding of what makes a good photo at your disposal, you could easily create amazing and engaging photos – all without having to buy expensive equipment or an expensive course.
In this post, I will try to walk through what makes a good photo (maybe even a great one) and how one can ensure they take one. When we are done, I am sure you will know exactly what needs to be done and gives you the required confidence.
So let's dive in-
Elements of a Good Photo –
So what is a Good photo?
You might say the answer to this is subjective –
- some would say a good photo is one which captures a wonderful memory or a moment in time for all eternity,
- for some, it would be something unique in the scene like a star trail or the milky way etc.
There could literally be dozens of reasons but as photographers, we tend to be a bit more technical 🙂
So as it goes, a seasoned photographer once explained to me the elements which make a good photo:
It should be well Exposed
When we talk about a well-exposed photo what we mean is that the photo has properly captured the available light in your scene.
There are no highs or lows with respect to the highlights and shadows. Nothing is too dark or too bright but just correct.
It should have proper Sharpness
When I talk about sharpness it means the elements in the scene are clear without any blurring or softness or any noise.
Now an image may usually not have sharpness due to any of the following reasons:
- The shifting of focus from the intended subject to something else
- The shutter speed is too slow causing camera shake, leading to a blurry photo
- This could also be as a result of your lens having some issues
To get the best sharpness ensure the following-
- Make sure to keep your ISO at your lowest possible value, higher ISO values add digital noise to the image. Also, check which is the highest ISO that your camera can handle without noticeable noise and set your Auto ISO max setting to that number.
- Set the metering mode to Matrix in Nikon cameras or Evaluative in Canon (I think) so that the whole scene is used by the camera to calculate the available light. This should work in most cases.
It should have been shot in RAW format
Here's the thing:
The modern digital camera, unlike the film based camera, uses a memory card to save the photos.
As a result of this, a modern day photographer has the freedom to choose between 2 file formats in which one can capture the photos onto the memory cards: Jpeg and RAW.
For definitive image quality, exposure control, and shadow/highlight detail, Raw is the best choice.
For speed and maximum storage space, use Jpeg.
So why should you shoot in RAW?
The biggest advantage of capturing images in Raw is the advantage you get in post–processing the image. So here's the technicality:
Any image in RAW format is in an uncompressed format much like an undeveloped film negative and gives the photographer the option to process and enhance or tweak the photo if needed using a software like Adobe Photoshop or Adobe Photoshop Lightroom. Listing all the advantages of shooting in RAW is beyond the scope of this post but I do intend to write another post specific to the same.
It should tell some story
An important element of a good photo is that it should reveal a story or intrigue within it.
Not every photo taken would have this element but the ones which do will add an extra bit of dimension and make the viewer even more interested to know –
what is the story behind the subject?
what are they thinking about?
It should have good composition
Composition is a way of guiding someone viewing the photo towards the most important elements in your scene, sometimes in a very specific order.
Composition is the placement of subjects and background in your photo. A good composition can help make a masterpiece even out of the dullest objects in the scene.
On the other hand, a bad composition can totally ruin a photograph, despite however interesting the subject may be. Having an expensive lens or camera will not guarantee you getting a good composition
So what does?
Well, it requires a lot of practice and believe me I am still getting the hang of it. So whenever you shoot, take a few seconds to choose a good composition taking into account the following things:
- Instead of placing your subject in the centre of the frame as we tend to as beginners, place the subject one-third of the way through the frame. This is the Rule of Thirds. In this case, you imagine that there are invisible lines – two horizontal and two vertical – dividing your picture into nine sections. Placing your subject on any of the points where the lines intersect, makes for a good composition.
- Ensure that the lines in the scene are straight and not crooked, so in the case of the horizon, it should be horizontally straight and in the case of buildings it should be vertically straight.
- When capturing any subject moving or looking in a particular direction, leaving room in front of the subject makes for a better composition.
- Avoid things in the background which might spoil the composition such as a tree branch appearing behind someone's head.
- You can use lines which in photography terms are called as Leading lines, to draw the viewer's attention to elements in the photo and it also adds a sense of depth to the photo.
- Using frames can add depth to the picture. Frames can windows, doors, trees or anything which surrounds the concerned subject.
- Trying to shoot from different angles can also give interesting viewpoints.
In conclusion:
These are just some of the tips and suggestions I have learned to take good photos and in no ways is this an exhaustive list.
The best thing to do as always is to keep on practising and experimenting for yourself and have fun.
As a beginner, you also tend to make some mistakes and if you want to correct a few common ones you can go ahead and read this article on beginner photography mistakes.


text:
Haryana Staff Selection Commission has recently announced the new recruitment notification for Shift Attendant posts on the official site. After completing the applying process now the department thought for issuing exam admit card on the main portal. Applied candidates can check and download it shortly until they can also check other related information on the department's official website.
HSSC Shift Attendant Admit Card 2016 | Online Exam Date
The Haryana Staff Selection Commission is a state level authorized organization; it has recruit staff for various posts in different-different offices. Department has conduct most of recruitment examinations every year for providing best quality employees there. At the time of recruitments the HSSC department has used the functions as Written Exam and personal Interviews as per requirements.
HSSC Shift Attendant Admit Card 2016 Online Download
The HSSC Shift Attendant Admit Card 2016 will be uploads very early on the main website http://www.hssc.gov.in/. Applicants please visit on the official website time to time and check exam related information there. Candidates can check other important information's or updations as Exam Date, Exam Pattern, Syllabus and other more. Candidates also connect with us, we will provides latest updations on our main portal.
For more other information's regarding to the Shift Attendant Admit Card 2016, please visit on the official website of Haryana Staff Selection Commission.